Preserved triamcinolone more likely to cause non-infectious endophthalmitis

Article

Non-infectious endophthalmitis is observed more frequently after injections of triamcinolone acetonide that contain preservatives (PTA) than after injections of preservative-free triamcinolone acetonide (PFTA), according to a study published online ahead of print in the British Journal of Ophthalmology.

Non-infectious endophthalmitis is observed more frequently after injections of triamcinolone acetonide that contain preservatives (PTA) than after injections of preservative-free triamcinolone acetonide (PFTA), according to a study published online ahead of print in the British Journal of Ophthalmology.

Mauricio Maia and colleagues from the Federal University of Sao Paulo, Brazil conducted a retrospective review of 646 intravitreal 4 mg steroid injections in 471 eyes. A total of 577 intravitreal injections of PFTA and 69 injections of PTA were administered in non-randomized eyes. Non-infectious endophthalmitis was defined as pseudohypopyon/hypopyon with or without an inflammatory reaction that regressed after steroid eye drop instillation. Ocular hypertension was defined as more than 23 mmHg with Goldmann applanation tonometry. Subjects were examined one, seven and 28 days post-injection and three, four, six and twelve months after injections.

Ocular hypertension was present in 127 eyes (20%), neither group differing significantly (p=0.167). Four eyes (3.2%) required trabeculectomy. Non-infectious endophthalmitis developed in 12 eyes (1.9%) and varied significantly in both groups (p=0.005); the majority of cases appeared in the PTA group. One eye developed bacterial endophthalmitis (0.15%).

The results revealed that non-infectious endophthalmitis develops more commonly after injections of PTA than after injections of PFTA.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.